Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BV601
- Development stage
- Phase 1
- Lead developer
- Wuhan BravoVax
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
BV601 is a recombinant hexavalent human papillomavirus (HPV) vaccine developed by Wuhan BravoVax. It is designed to provide protection against six high-risk and low-risk HPV genotypes: 6, 11, 16, 18, 52, and 58. The vaccine utilizes virus-like particle (VLP) technology, where the L1 major capsid proteins of the targeted HPV types are expressed in a yeast system (typically *Hansenula polymorpha*) and self-assemble into VLPs that mimic the viral structure without being infectious. BV601 is intended to prevent HPV-related conditions, including cervical cancer, vulvar cancer, vaginal cancer, and genital warts (condyloma acuminata). As of 2024, the candidate is in Phase I clinical trials to assess its safety, tolerability, and immunogenicity in healthy adult populations.
- Other names
- BravoVax 6-valent HPV vaccineBravoVax6-valent HPV vaccineBravoVax-6-valent HPV vaccineHexavalent HPV vaccine (BravoVax)
02
Targets
HPV16 (Human papillomavirus type 16)HPV31 L1HPV45 L1HPV18 L1HPV52 L1 (Human papillomavirus type 52 major capsid protein L1)TLR4 (Toll-like receptor 4)HPV6 L1 (Human papillomavirus type 6 major capsid protein L1)HPV11 L1HPV33 L1HPV58 L1 (Human papillomavirus type 58 major capsid protein L1)
Beyond the preview
Go deeper on BV601.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BV601.